A serum magnesium of 2.46 mg/dL is NOT a contraindication to doxorubicin and cyclophosphamide chemotherapy.
This mild hypermagnesemia does not appear in any established contraindications for these agents and should not delay cancer treatment that impacts survival.
Analysis of Contraindications
The FDA-approved prescribing information for cyclophosphamide lists only two absolute contraindications 1:
- Severe hypersensitivity reactions to cyclophosphamide or its metabolites
- Urinary outflow obstruction
Hypermagnesemia is not mentioned as a contraindication in any guideline or drug label for either doxorubicin or cyclophosphamide.
Context of This Magnesium Level
A serum magnesium of 2.46 mg/dL represents mild hypermagnesemia (normal range: 1.7-2.2 mg/dL). This elevation is:
- Clinically insignificant at this level - severe symptoms typically occur above 4-6 mg/dL
- Not associated with cardiac contraindications to anthracyclines or alkylating agents
- Far below dangerous levels - the fatal cases reported involved levels of 9.9-11.0 mg/dL 2
Primary Concerns with These Agents
The major contraindications and monitoring requirements for doxorubicin-cyclophosphamide focus on entirely different organ systems 3, 4:
Cardiac monitoring priorities:
- Baseline and serial LVEF assessment (not magnesium)
- Cumulative doxorubicin dose limits (400-550 mg/m²)
- Pre-existing cardiac disease
- Prior chest radiation
Renal/urologic monitoring:
- Urinary outflow obstruction (absolute contraindication for cyclophosphamide)
- Adequate hydration to prevent hemorrhagic cystitis
- Renal function for dose adjustment
Clinical Recommendation
Proceed with planned chemotherapy. The mild hypermagnesemia should be:
- Investigated for cause (magnesium-containing medications, supplements, renal function)
- Corrected if possible by discontinuing unnecessary magnesium sources
- Monitored but not considered a barrier to treatment
The ASCO guidelines 5 and NCCN guidelines 6 extensively detail doxorubicin-cyclophosphamide regimens without any mention of magnesium levels as a consideration for treatment eligibility.
Critical Pitfall to Avoid
Do not delay potentially curative or life-extending chemotherapy for mild electrolyte abnormalities that are not established contraindications. The mortality and morbidity risks from untreated or delayed cancer treatment far exceed any theoretical risk from this magnesium level. Recent research even suggests that elevated magnesium may be associated with favorable cancer outcomes 7, though this is not directly applicable to your question about contraindications.